Company news
Bluenergies Ltd. news in 2007
Bluenergies Ltd.'s news releases, calls and decks from 2007, newest first.
Neurochem announces European opinion for Eprodisate (KIACTA(TM)) for the treatment of AA amyloidosis
December 14, 2007
Neurochem announces eprodisate (KIACTA(TM)) receives acknowledgement of complete response and is granted Class 2 review
December 6, 2007
Neurochem announces departure of Dr. Philippe Calais, President, Global Business
November 30, 2007
Neurochem announces important initiatives to provide medical and health benefits to patients
November 8, 2007
Neurochem reports results for third quarter of fiscal 2007
November 7, 2007
Neurochem provides information on cash position
August 28, 2007
Neurochem Announces results from Tramiprosate (ALZHEMED(TM)) North American Phase III Clinical Trial
August 26, 2007
Neurochem reports results for second quarter of fiscal 2007
August 9, 2007
Neurochem granted Fast Track designation from U.S. FDA for tramiprosate (ALZHEMED(TM))
July 24, 2007
Neurochem receives approvable letter for eprodisate (KIACTA(TM)) for treatment of AA amyloidosis
July 17, 2007
Neurochem to present at Jefferies Healthcare Conference
June 26, 2007
Tramiprosate (ALZHEMED(TM)) North American Phase III clinical trial progress update
June 22, 2007
Neurochem receives third recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
June 21, 2007
Neurochem Announces Mandatory and Full Conversion of All Oustanding Senior Subordinated Convertible Notes
June 18, 2007
At the 2007 Alzheimer's Association International Conference on the Prevention of Dementia - Neurochem's U.S. Principal Investigator Presents Update on Tramiprosate (ALZHEMED(TM))
June 11, 2007
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis
June 7, 2007
Neurochem announces it has obtained written consent from its shareholders in connection with its private placement of US$80 million aggregate principal amount of convertible notes
June 5, 2007
Neurochem reports results for first quarter of fiscal 2007
May 8, 2007
At Annual General Meeting of Shareholders (AGM) - Neurochem provides update on core product candidates and recent financing of us$80 million
May 8, 2007
Market Regulation Services - Trade Resumption - Neurochem Inc. - NRM
May 2, 2007
Neurochem Announces Private Placement of US$80 Million Aggregate Principal Amount of 6% Senior Convertible Notes and 5% Senior Subordinated Convertible Notes
May 2, 2007
Market Regulation Services - Trading Halt - Neurochem Inc. - NRM
May 2, 2007
Neurochem Update on the North American Phase III Clinical Trial for Tramiprosate (ALZHEMED(TM)) for the Treatment of Alzheimer's Disease
April 19, 2007
Neurochem's eprodisate (KIACTA(TM)) PDUFA date extended three months by FDA
April 11, 2007
Neurochem reports results for fourth quarter and fiscal year 2006
February 21, 2007
Neurochem receives second recommendation from European Data Safety Monitoring Board to continue Phase III clinical trial for tramiprosate (ALZHEMED(TM))
February 13, 2007
Neurochem announcement regarding the completion of its North American phase III clinical trial for tramiprosate (ALZHEMED(TM)) for the treatment of Alzheimer's disease
February 1, 2007
Neurochem files shelf prospectus in connection with previously announced equity line of credit facility and convertible notes financings
January 17, 2007
Neurochem announces appointment of John Bernbach to Board of Directors
January 16, 2007